Meeting
2023 ASCO Annual Meeting
A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma.
Authors
Daniel Olson
University of Chicago, Chicago, IL
Daniel Olson , Young Hong , Sajeve Samuel Thomas , Juan Martin-Liberal , Friedrich Graf Finckenstein , Renee Xiao Wu , Giri Sulur , Wen Shi , James Larkin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT05727904
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS9607)
DOI
10.1200/JCO.2023.41.16_suppl.TPS9607
Abstract #
TPS9607
Poster Bd #
362b
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Safety and efficacy of lifileucel (LN-144), an autologous, tumor infiltrating lymphocyte cell therapy in combination with pembrolizumab for immune checkpoint inhibitor naïve patients with advanced melanoma.
First Author: Sajeve Samuel Thomas
Poster
2019 ASCO Annual Meeting
Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1.
First Author: Amod Sarnaik
Poster
2018 ASCO Annual Meeting
A phase 2 study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (TIL, LN-145) alone and in combination with anti-PD-L1 inhibitor durvalumab in patients with locally advanced or metastatic NSCLC.
First Author: Sylvia Mina Lee
Poster
2019 ASCO Annual Meeting
Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma.
First Author: Amir A. Jazaeri